D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) announced plans to partner on a joint proof-of-concept project to explore the use of quantum computing technology and artificial intelligence (“AI”) to accelerate the speed and quality of the drug discovery process, i.e., “Quantum AI-driven Drug Discovery.” The project aims to pioneer a new process for discovering ‘first-in-class’ pharmaceutical small compounds. Upon completion of the proof-of-concept project, JT’s pharmaceutical division intends to further advance the developed Quantum AI-driven Drug Discovery analysis systems and eventually apply the quantum computing technology in production operations.
“Pharmaceutical companies need to maintain competitiveness while addressing the challenges of difficulty, uncertainty, and duration in new drug development, creating an environment that is accelerating the speed and quality for AI drug discovery,” said Dr. Alan Baratz, CEO of D-Wave. “D-Wave is committed to supporting JT’s pharmaceutical division in maximizing the capabilities of AI through quantum computing technology, with the goal of expanding the exploration space for pharmaceutical small compounds.”
To view the full press release, visit https://ibn.fm/KOinv
About D-Wave Quantum Inc.
D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
